- Trial phase
- Not stated
- Time to market
- Not stated
- Why 2/10
- No dated catalyst exists for AB102 because the drug cannot be identified in any public source. ImpactScore defaults to 2, a preclinical/undisclosed program with no scheduled catalyst within the next 12 months.
AB102 is not identifiable in any public database or filing associated with Arcus Biosciences. Investors should not base any trading decisions on this drug name until the company formally discloses it in a pipeline update, SEC filing, or press release. Monitor Arcus' upcoming Q3 2026 earnings call (expected late October/early November 2026) for any pipeline updates.
Price Chart
Executive Summary
No publicly available information could be found about a drug candidate called "AB102" in association with Arcus Biosciences (RCUS) or any other developer. The drug name does not appear in SEC filings, clinical trial registries, FDA databases, press releases, or any internal SecBot data sources. Arcus Biosciences' known pipeline consists of domvanalimab, zimberelimab, etrumadenant, quemliclustat, and casdatifan, none of which match the code "AB102." This drug is either an extremely early-stage/preclinical asset not yet publicly disclosed, or the code may belong to a different company entirely.
How It Works
Unknown, no mechanism information is publicly available for AB102.
Trial Status
No clinical trials, regulatory filings, or press releases referencing AB102 were found in any searched database.
The Two-Sided Case
Upcoming Catalysts
- No AB102-specific catalysts identified. For RCUS broadly: Q3 2026 earnings (est. late Oct/early Nov 2026), casdatifan data updates, domvanalimab Phase 3 readout from completed STAR-121 trial (NCT05568095, 1,040 patients, completed Aug 2026).
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Arcus Biosciences, Inc. 8-K RCUS ·Originating report